Poseida Therapeutics Stock Revenue
| PSTX Stock | USD 9.31 0.02 0.21% |
Poseida Therapeutics fundamentals help investors to digest information that contributes to Poseida Therapeutics' financial success or failures. It also enables traders to predict the movement of Poseida Stock. The fundamental analysis module provides a way to measure Poseida Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Poseida Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Total Revenue | 64.7 M | 67.9 M |
Poseida | Revenue |
Poseida Therapeutics Company Revenue Analysis
Poseida Therapeutics' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Poseida Therapeutics Revenue | 64.7 M |
Most of Poseida Therapeutics' fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Poseida Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Historical and Projected quarterly revenue of Poseida
Projected quarterly revenue analysis of Poseida Therapeutics provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Poseida Therapeutics match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Poseida Therapeutics' stock price.
Poseida Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for Poseida Therapeutics is extremely important. It helps to project a fair market value of Poseida Stock properly, considering its historical fundamentals such as Revenue. Since Poseida Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Poseida Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Poseida Therapeutics' interrelated accounts and indicators.
| 0.62 | 0.64 | 0.25 | 0.49 | -0.21 | ||
| 0.62 | 0.52 | -0.31 | 0.95 | 0.24 | ||
| 0.64 | 0.52 | -0.23 | 0.27 | 0.03 | ||
| 0.25 | -0.31 | -0.23 | -0.38 | -0.68 | ||
| 0.49 | 0.95 | 0.27 | -0.38 | 0.36 | ||
| -0.21 | 0.24 | 0.03 | -0.68 | 0.36 |
Click cells to compare fundamentals
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Poseida Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Poseida Therapeutics reported 64.7 M of revenue. This is 99.15% lower than that of the Biotechnology sector and 91.29% lower than that of the Health Care industry. The revenue for all United States stocks is 99.31% higher than that of the company.
Poseida Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Poseida Therapeutics' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Poseida Therapeutics could also be used in its relative valuation, which is a method of valuing Poseida Therapeutics by comparing valuation metrics of similar companies.Poseida Therapeutics is currently under evaluation in revenue category among its peers.
Poseida Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Poseida Therapeutics from analyzing Poseida Therapeutics' financial statements. These drivers represent accounts that assess Poseida Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Poseida Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Enterprise Value | 551.3M | 370.2M | 278.3M | 388.5M | 344.0M | 545.8M |
Poseida Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Poseida Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Poseida Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Poseida Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Poseida Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Poseida Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Poseida Therapeutics' value.| Shares | Jacobs Levy Equity Management, Inc. | 2024-09-30 | 811.5 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 726.6 K | Millennium Management Llc | 2024-06-30 | 643 K | Charles Schwab Investment Management Inc | 2024-09-30 | 567.1 K | Northern Trust Corp | 2024-09-30 | 565.4 K | Dimensional Fund Advisors, Inc. | 2024-09-30 | 563.1 K | Goldman Sachs Group Inc | 2024-06-30 | 501.9 K | Nuveen Asset Management, Llc | 2024-06-30 | 402.9 K | Wellington Management Company Llp | 2024-06-30 | 387.3 K | Fmr Inc | 2024-09-30 | 14.6 M | Pentwater Capital Management Lp | 2024-09-30 | 6 M |
Poseida Fundamentals
| Return On Equity | -0.58 | ||||
| Return On Asset | -0.13 | ||||
| Profit Margin | (0.40) % | ||||
| Operating Margin | 0.28 % | ||||
| Current Valuation | 759.29 M | ||||
| Shares Outstanding | 97.47 M | ||||
| Shares Owned By Insiders | 27.64 % | ||||
| Shares Owned By Institutions | 58.48 % | ||||
| Number Of Shares Shorted | 4.61 M | ||||
| Price To Earning | 214.00 X | ||||
| Price To Book | 10.40 X | ||||
| Price To Sales | 6.03 X | ||||
| Revenue | 64.7 M | ||||
| Gross Profit | (22.41 M) | ||||
| EBITDA | (109.04 M) | ||||
| Net Income | (123.43 M) | ||||
| Cash And Equivalents | 142.56 M | ||||
| Cash Per Share | 1.66 X | ||||
| Total Debt | 85.42 M | ||||
| Debt To Equity | 1.39 % | ||||
| Current Ratio | 3.69 X | ||||
| Book Value Per Share | 0.90 X | ||||
| Cash Flow From Operations | (92.17 M) | ||||
| Short Ratio | 8.30 X | ||||
| Earnings Per Share | (0.63) X | ||||
| Price To Earnings To Growth | (0.63) X | ||||
| Target Price | 9.5 | ||||
| Number Of Employees | 350 | ||||
| Beta | 0.54 | ||||
| Market Capitalization | 909.36 M | ||||
| Total Asset | 273.88 M | ||||
| Retained Earnings | (594.29 M) | ||||
| Working Capital | 155.16 M | ||||
| Current Asset | 10.59 M | ||||
| Current Liabilities | 5.1 M | ||||
| Net Asset | 273.88 M |
About Poseida Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Poseida Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Poseida Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Poseida Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Poseida Stock Analysis
When running Poseida Therapeutics' price analysis, check to measure Poseida Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Poseida Therapeutics is operating at the current time. Most of Poseida Therapeutics' value examination focuses on studying past and present price action to predict the probability of Poseida Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Poseida Therapeutics' price. Additionally, you may evaluate how the addition of Poseida Therapeutics to your portfolios can decrease your overall portfolio volatility.